Brokerages predict that Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) will post earnings of ($0.29) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Avadel Pharmaceuticals PLC.’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.35). Avadel Pharmaceuticals PLC. posted earnings of $0.11 per share in the same quarter last year, which suggests a negative year over year growth rate of 363.6%. The business is scheduled to report its next quarterly earnings results on Tuesday, March 6th.

On average, analysts expect that Avadel Pharmaceuticals PLC. will report full year earnings of $1.39 per share for the current fiscal year, with EPS estimates ranging from $1.30 to $1.46. For the next financial year, analysts expect that the firm will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.86) to ($0.74). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Avadel Pharmaceuticals PLC..

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.13. Avadel Pharmaceuticals PLC. had a net margin of 44.47% and a return on equity of 33.92%. The company had revenue of $39.68 million during the quarter, compared to the consensus estimate of $38.22 million. During the same period in the previous year, the business earned ($0.08) earnings per share. The firm’s quarterly revenue was up 23.7% on a year-over-year basis.

AVDL has been the subject of a number of analyst reports. Ladenburg Thalmann Financial Services lifted their price target on shares of Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a research report on Thursday, September 7th. Langenberg & Company reiterated a “buy” rating and issued a $30.00 price target (up from $27.00) on shares of Avadel Pharmaceuticals PLC. in a research report on Thursday, September 7th. Zacks Investment Research downgraded shares of Avadel Pharmaceuticals PLC. from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Finally, Roth Capital set a $15.00 price objective on shares of Avadel Pharmaceuticals PLC. and gave the company a “buy” rating in a research report on Wednesday, August 9th.

COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Avadel Pharmaceuticals PLC. (AVDL) to Post -$0.29 Earnings Per Share” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/18/brokerages-anticipate-avadel-pharmaceuticals-plc-avdl-to-post-0-29-earnings-per-share.html.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) traded up $0.13 during midday trading on Friday, hitting $9.23. 118,180 shares of the stock were exchanged, compared to its average volume of 168,162. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.01. Avadel Pharmaceuticals PLC. has a 52 week low of $8.14 and a 52 week high of $12.30. The firm has a market capitalization of $367.57, a P/E ratio of 17.00 and a beta of 1.41.

In related news, insider Greg J. Divis bought 10,600 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were purchased at an average price of $9.32 per share, with a total value of $98,792.00. Following the completion of the purchase, the insider now owns 10,600 shares in the company, valued at approximately $98,792. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael S. Anderson bought 4,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were bought at an average cost of $9.80 per share, for a total transaction of $39,200.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 46,855 shares of company stock valued at $445,058. Company insiders own 5.07% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of AVDL. Acadian Asset Management LLC grew its stake in shares of Avadel Pharmaceuticals PLC. by 9.7% during the second quarter. Acadian Asset Management LLC now owns 1,672,207 shares of the company’s stock worth $18,444,000 after buying an additional 147,907 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in shares of Avadel Pharmaceuticals PLC. by 27.9% during the second quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock worth $464,000 after buying an additional 9,175 shares during the last quarter. Sei Investments Co. grew its stake in shares of Avadel Pharmaceuticals PLC. by 29.5% during the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after buying an additional 2,900 shares during the last quarter. Trexquant Investment LP grew its stake in shares of Avadel Pharmaceuticals PLC. by 30.7% during the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock worth $336,000 after buying an additional 7,169 shares during the last quarter. Finally, Alps Advisors Inc. bought a new stake in shares of Avadel Pharmaceuticals PLC. during the second quarter worth $411,000. 69.56% of the stock is currently owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals PLC. Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals PLC. (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avadel Pharmaceuticals PLC. (NASDAQ:AVDL)

Receive News & Stock Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related stocks with our FREE daily email newsletter.